Maxcyte (MXCT) Profit After Tax (2020 - 2026)

Maxcyte (MXCT) has 7 years of Profit After Tax data on file, last reported at -$4.8 million in Q1 2026.

• On a quarterly basis, Profit After Tax rose 53.71% year-over-year to -$4.8 million in Q1 2026; TTM through Mar 2026 was -$39.1 million, a 6.39% increase from a year earlier, with the FY2025 full-year figure at -$44.6 million, down 8.71% from the prior year.
• Profit After Tax for Q1 2026 stood at -$4.8 million, up from -$9.6 million in the prior quarter.
• Over the last five years, Profit After Tax for MXCT reached as high as -$4.1 million in Q1 2022 and fell as low as -$12.4 million in Q3 2025.
• Historically, Profit After Tax has averaged -$8.9 million across 5 years, with a median of -$9.6 million in 2025.
• Across the five-year window, Profit After Tax slumped 167.55% in 2023 and soared 53.71% in 2026, its largest moves.
• Year by year, Profit After Tax stood at -$4.8 million in 2022, then retreated by 9.74% to -$5.3 million in 2023, then slumped by 100.78% to -$10.6 million in 2024, then advanced by 9.45% to -$9.6 million in 2025, then soared by 50.5% to -$4.8 million in 2026.
• Per Business Quant data, the three most recent Profit After Tax figures were -$4.8 million in Q1 2026, -$9.6 million in Q4 2025, and -$12.4 million in Q3 2025.